 Onward and upward the market goes, with December providing further cheer as new record highs for the SP; 500 were notched in the last week. Giddy from 2019s riches and ready to bring in the New Year, the optimism on the Street, following a brief slump, has been renewed.While analysts are divided as to whether the next year can follow this ones record breaking run, one thing looks certain; investors will still be on the lookout for the right addition to their portfolio.TipRanks - a company that tracks and measures the performance of analysts - has an instrument that comes in handy here. The Daily Stock Ratings tool allows a user to see what stocks are hot and, yes, what stocks are not. Analysts ratings and their performances are displayed, too, further helping the intrepid investor make the right decision.Lets have a look, then, at 3 Buy-rated stocks a number of the Streets leading analysts recently pulled the trigger on.Stemline Therapeutics Inc STMLWith a focus on developing and bringing to market novel oncology therapies, Stemline Therapeutics has recently been turning heads on the Street.The New York based biotech has several therapies in the pipeline, but already has one on the market. Elzonris is used to treat a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm BPDCN, and was approved by the FDA in December 2018 for the treatment of adults and pediatric patients over 2 years old. The drug is currently in clinical trials to assess further indications.Cantor Fitzgeralds Alethia Young calls Elzonris a pipeline in a product and believes the biotech is undervalued. Stemlines market cap is currently 555.4 million, and Young expects sales from Elzonris for BPDCN sans maintenance therapy to be in the region of 150 million by 2025. Were talking about just the US here. Furthermore, the 5-star analyst thinks the possible expansion of Elzonris into the BPDCN maintenance setting in 2021 could, by 2029, result in US sales of 223M. Young maintains that as as investors take notice of progress in the label expansion opportunities, the next 12 months should see Stemlines share price take off.Accordingly, Young initiated coverage on Stemline with an Overweight rating and set a price target of 18. This implies upside potential of 62 over the next 12 months. To watch Youngs track record, click hereThe Cantor analysts bullish thesis is mirrored by that of the Streets. All 5 analysts tracked over the last three months rate the stock a Buy, and therefore, Stemline has a Strong Buy consensus rating. An average price target of 22.75 outstrips Youngs target and indicates gains of 105 could be in the cards. See Stemline stock analysis on TipRanks X4 Pharmaceuticals Inc XFORThe biotech sectors recent upturn in the market hasnt, unfortunately, had any effect on X4 Pharmaceuticals. The rare disease focused biotech has had a rough year in the market, and its share price is down by 21 year-to-date. The word on the Street, though, is that this is all about to change.The company has several drugs in the pipeline, but its lead candidate is mavorixafor X4P-001, currently in Phase 3 development for the treatment of WHIM syndrome. The rare, inherited condition is an immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Designated orphan status by the FDA in 2018, the drug is also in development for several other conditions, including Waldenströms macroglobulinemia WM.Roth Capitals Zegbeh Jallah highlights XFORs well experienced team which includes Dr. Renato Skerlj, who developed the first CXCR4 antagonist plerixafor, as making it a stand-out. Jallah also bases his bullish thesis on a strong conviction around the clinical and commercial outlook of mavorixafor, and a robust pipeline of optimized CXCR4 modulators that could offer improved benefits across a broader range of diseases. As a result, the analyst initiated coverage of X4 with a Buy rating and a price target of 20, indicating handsome upside potential of 82. To watch Jallahs track record, click hereA fellow analyst praising XFOR is Oppenheimers Leland Gershell. The 5-star analyst expects the drug to gain approval for WHIM syndrome and remains cautiously optimistic about its part to play in Waldenstroms macroglobulinemia. Leland initiated coverage with an Outperform rating and a price target of 20, too. To watch Gershells track record, click here3 other analysts have chipped in with a take on X4 over the last three months and all have reached the same conclusion: Buy. Therefore, the rare disease specialist has a Strong Buy consensus rating. The average price target of 20.25 could provide investors with gains of 84 over the next 12 months. See X4 Pharmaceuticals stock analysis on TipRanks See also: 3 Strong Buy Energy Stocks with Electric Upside PotentialiMedia Brands Inc IMBIMoving on from the biotech industry, we encounter a fellow struggler. Although in a completely different industry, multiplatform commerce company iMedia Brands hasnt had much joy in 2019, either. Languishing in the doldrums, the company has a year-to-date loss of 7.That being said, iMedia has an expanding portfolio of shopping television networks and new media businesses including ShopHQ and iMedia Web Services. November saw new additions to the list, too. The first, Float Left Interactive, an OTT over the top and TVE TV everywhere service provider, has launched a string of OTT apps and counts NBC, Comcast and CBS among its clients. The second, J.W. Hulme, is a maker of leather bags and accessories, and will get its own programming on ShopHQs cable channel.So, with the new developments in place, is now the right time to get in on iMedia? It is according to D.A. Davidsons Tom Forte. The 5-star analyst forecasts iMedia revenue to grow by 3 per year over the next three years and projects that by 2022, the companys EBITDA margin will expand by almost 500 basis points to 3.1.Furthermore, with LaVenta, the companys new omni-channel, Spanish language, television shopping network launching in Q1 2020, Forte acknowledges iMedias potential for expansion outside the US.To this end, Forte initiated coverage on the interactive media company with a Buy rating, alongside a price target of 10. The bullish target indicates upside potential of a whopping 170. To watch Fortes track record, click hereiMedia currently has only 1 other analyst assessing the companys 12-month potential, but he happens to be a vocal fan, too. Lake Streets Mark Argento reckons the next year could see iMedias share price reach 15, which lends itself to a massive 305 increase from the current price. To watch Argentos track record, click herePut together, the media company has a Moderate Buy consensus rating and an average price target of 12.50. Potentially, then, investors could be lining their pockets with a 237 gain next year. See iMedia price targets and analyst ratings on TipRanks 